Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs UV 4 (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Emergent BioSolutions; Unither Pharmaceuticals
- 28 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Aug 2014 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 09 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.